Q-omics provides the consensus-scored BOLA3P4 profile across patient tissues and cancer cell-line models. BOLA3P4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BOLA3P4 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, BOLA3P4 RNA expression shows 6,635 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, BRCA, and STAD as cancer lineages where BOLA3P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BOLA3P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BOLA3P4 survival associations across molecular data types. BOLA3P4 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BOLA3P4 RNA expression–survival associations across cancer types. High BOLA3P4 expression shows unfavorable associations in ACC, KIRC, LUAD and THYM, but favorable associations in MESO and STAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for BOLA3P4 RNA expression.
This table summarizes BOLA3P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for BOLA3P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BOLA3P4 shows lower tumor expression in THCA, PAAD and READ and higher tumor expression in BRCA. The BRCA box plot shows higher BOLA3P4 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p = .014).
This table shows molecular features associated with BOLA3P4 in patient tissues and cancer cell lines. In patient samples, BOLA3P4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
